Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study

Trial Profile

Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2014

At a glance

  • Drugs Lipegfilgrastim (Primary)
  • Indications Febrile neutropenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioGeneriX; Teva Pharmaceutical Industries
  • Most Recent Events

    • 24 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top